Cibus Inc
CBUS1.535USD
+0.045+3.02%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
50.13MCap. mercado
PérdidaP/E TTM
Más Datos de Cibus Inc Compañía
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
Información de la empresa
Símbolo de cotizaciónCBUS
Nombre de la empresaCibus Inc
Fecha de salida a bolsaJul 20, 2017
Director ejecutivoDr. Peter Ronald Beetham, Ph.D.
Número de empleados157
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 20
Dirección6455 Nancy Ridge Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121
Teléfono18584500008
Sitio Webhttps://www.cibus.com/
Símbolo de cotizaciónCBUS
Fecha de salida a bolsaJul 20, 2017
Director ejecutivoDr. Peter Ronald Beetham, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rory B. Riggs
Mr. Rory B. Riggs
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
14.63M
+396.82%
Dr. Peter Ronald Beetham, Ph.D.
Dr. Peter Ronald Beetham, Ph.D.
President, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, Director
President, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, Director
382.44K
--
Dr. Greg Gocal, Ph.D.
Dr. Greg Gocal, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
374.84K
+19.06%
Mr. Jason Stokes, Esq.
Mr. Jason Stokes, Esq.
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
127.67K
--
Ms. Noel Sauer, Ph.D.
Ms. Noel Sauer, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
105.48K
--
Dr. Gerhard Prante, Ph.D.
Dr. Gerhard Prante, Ph.D.
Independent Director
Independent Director
40.20K
+421.56%
Mr. Cornelis (Carlo) Broos
Mr. Cornelis (Carlo) Broos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. August J. Moretti, J.D.
Mr. August J. Moretti, J.D.
Independent Director
Independent Director
--
--
Mr. Jean-Pierre Lehmann
Mr. Jean-Pierre Lehmann
Independent Director
Independent Director
--
--
Mr. Mark Finn
Mr. Mark Finn
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rory B. Riggs
Mr. Rory B. Riggs
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
14.63M
+396.82%
Dr. Peter Ronald Beetham, Ph.D.
Dr. Peter Ronald Beetham, Ph.D.
President, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, Director
President, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, Director
382.44K
--
Dr. Greg Gocal, Ph.D.
Dr. Greg Gocal, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
374.84K
+19.06%
Mr. Jason Stokes, Esq.
Mr. Jason Stokes, Esq.
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
127.67K
--
Ms. Noel Sauer, Ph.D.
Ms. Noel Sauer, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
105.48K
--
Dr. Gerhard Prante, Ph.D.
Dr. Gerhard Prante, Ph.D.
Independent Director
Independent Director
40.20K
+421.56%
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.03M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Riggs (Rory B)
30.24%
Fidelity Management & Research Company LLC
9.50%
Armistice Capital LLC
4.03%
JPL Investments SA
3.46%
Vantage Consulting Group, Inc.
2.36%
Other
50.40%
Accionistas
Accionistas
Proporción
Riggs (Rory B)
30.24%
Fidelity Management & Research Company LLC
9.50%
Armistice Capital LLC
4.03%
JPL Investments SA
3.46%
Vantage Consulting Group, Inc.
2.36%
Other
50.40%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
32.86%
Investment Advisor
14.99%
Investment Advisor/Hedge Fund
4.99%
Hedge Fund
4.12%
Corporation
3.55%
Family Office
0.44%
Research Firm
0.29%
Bank and Trust
0.09%
Other
38.69%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
166
29.51M
61.00%
+13.82M
2025Q1
171
17.83M
39.89%
+256.22K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Riggs (Rory B)
14.63M
30.24%
+11.68M
+396.82%
Jun 09, 2025
Fidelity Management & Research Company LLC
4.60M
9.5%
+647.11K
+16.38%
Mar 31, 2025
Armistice Capital LLC
1.95M
4.03%
+1.95M
--
Mar 31, 2025
JPL Investments SA
1.67M
3.46%
-12.28K
-0.73%
Mar 24, 2025
Vantage Consulting Group, Inc.
1.14M
2.36%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.03M
2.13%
-16.63K
-1.59%
Mar 31, 2025
The Vanguard Group, Inc.
892.12K
1.84%
+41.63K
+4.90%
Mar 31, 2025
Geode Capital Management, L.L.C.
473.61K
0.98%
+81.22K
+20.70%
Mar 31, 2025
Beetham (Peter Ronald)
382.44K
0.79%
--
--
Mar 24, 2025
Gocal (Gregory Francis William)
374.84K
0.77%
+60.00K
+19.06%
Mar 24, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
